Historically, treatment options for focal segmental glomerulosclerosis (FSGS) have been limited to high-dose corticosteroids or calcineurin inhibitors in those ineligible or intolerant to steroids. However, an increase in clinical trial activity in the field of kidney disease may carry hope for novel therapeutic options for FSGS. This is illustrated by the recent approval of dapagliflozin for chronic kidney disease.
In this episode, Dr. Kirk Campbell offers his expert opinion into the potential clinical implications of current and investigational therapies, both now and in the future.
Learning objective
After listening to this podcast series, learners will be able to recall the potential clinical implications of current and investigational therapies for FSGS.
Disclosures
Dr. Kirk Campbell declares the following financial relationships from the past 24 months:
Consultant - ANI, Calliditas, Chinook, Travere
Research/grant support - Vertex
Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labelling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labelled for the use under discussion.
Funding:
This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.